Find in Library

<strong>Objective-</strong> Because little information was available in the literature about the angiogenic property of enrofloxacin, this investigation was undertaken to evaluate this aspect using an <em>in vivo</em>model.<br /> <strong>Design- </strong>Experimental study.<br /> <strong>Animals-</strong> Twenty fertile chicken eggs (Ross 308) with the average egg-weight of 55 ± 0.4 g were randomly divided into experimental and control groups.<br /> <strong>Procedures-</strong> Agar pellets were prepared with enrofloxacin concentrations at a dosage of 10 mg/Kg egg-weight. A window was carved on the eggshell and drug-impregnated pellet applied on day 8 of incubation on the surface of the chick chorioallantoic membrane. The response of vascular plexus to the drug application was evaluated.<br /> <strong>Results-</strong> Our results showed that enrofloxacin decrease angiogenesis as shown by a reduction in the morphometric parameters of vascular plexus including total vessel's length, the number of vascular branch, vascular complexity and capillary density (p<0.05).<br /> <strong>Conclusion and Clinical Relevance-</strong> Based on findings, it is suggested that enrofloxacin offer a new class of anti-angiogenic agents that might augment the drugs available for the clinical treatment of angiogenesis related diseases.